Apr. 2, 2021—Chancellor Daniel Diermeier presented prestigious awards to seven academic leaders at the Spring Faculty Assembly on April 1. He also announced the establishment of the Chancellor's Award for University Service.
Coronavirus experts discuss importance of research investments, lessons learned from COVID-19 at Chancellor’s Lecture Series
Mar. 24, 2021—Vanderbilt’s role in shaping each step of the medical response to the COVID-19 pandemic began three decades ago and is grounded in the determination of a small group of scientists to understand coronaviruses. The research, and the faculty and alumni who helped lead it, was the topic of the March 23 Chancellor’s Lecture Series virtual event, “Vanderbilt in the Vanguard: The Decades-Long Journey to a Coronavirus Vaccine.”
Mar. 15, 2021—Vanderbilt scientists on the front lines of COVID-19 research will share their insights on the pandemic and subsequent vaccine development during a Chancellor’s Lecture Series event on Tuesday, March 23, at 5 p.m. CT, hosted by Chancellor Daniel Diermeier.
Feb. 15, 2021—Vanderbilt first-year students recently met with Buddy Creech, director of the Vanderbilt Vaccine Research Program and associate professor of pediatrics, for a special virtual chat to answer some of their COVID-19 vaccine questions.
Dec. 18, 2020—Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes.
Dec. 16, 2020—One of the world’s foremost experts on coronaviruses, Dr. Mark R. Denison, shared his research and insights into COVID-19 during a webinar on Dec. 14. A video of the webinar is now available for viewing.
Dec. 9, 2020—Chancellor Daniel Diermeier will host a special presentation with coronavirus expert Dr. Mark R. Denison on Monday, Dec. 14, from 11 a.m. to noon Central time. Denison’s presentation, “Preparing for the COVID-19 Pandemic ... for 36 Years,” will explore why COVID-19 emerged, his lab’s discoveries, and where we go from here.
Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.
Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.
May. 14, 2020—From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic.
Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.